Savant Capital LLC Sells 662 Shares of Kenvue Inc. (NYSE:KVUE)

Savant Capital LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,531 shares of the company’s stock after selling 662 shares during the period. Savant Capital LLC’s holdings in Kenvue were worth $227,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Clearstead Advisors LLC bought a new position in shares of Kenvue in the third quarter worth about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC bought a new position in Kenvue in the 3rd quarter worth approximately $28,000. EverSource Wealth Advisors LLC acquired a new position in Kenvue during the 3rd quarter worth $28,000. Finally, Cullen Frost Bankers Inc. bought a new position in Kenvue in the 3rd quarter valued at $29,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Royal Bank of Canada cut their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein began coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. Finally, The Goldman Sachs Group began coverage on shares of Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Stock Performance

KVUE stock opened at $20.08 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80. The stock has a 50-day moving average price of $19.85 and a two-hundred day moving average price of $20.11.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. Analysts expect that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 3.98%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.